These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 21270790)

  • 21. Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians.
    Schelleman H; Chen Z; Kealey C; Whitehead AS; Christie J; Price M; Brensinger CM; Newcomb CW; Thorn CF; Samaha FF; Kimmel SE
    Clin Pharmacol Ther; 2007 May; 81(5):742-7. PubMed ID: 17329985
    [TBL] [Abstract][Full Text] [Related]  

  • 22. VKORC1 V66M mutation in African Brazilian patients resistant to oral anticoagulant therapy.
    Orsi FA; Annichino Bizzacchi JM; de Paula EV; Ozelo MC; Langley MR; Weck KE
    Thromb Res; 2010 Sep; 126(3):e206-10. PubMed ID: 20615525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians.
    Suriapranata IM; Tjong WY; Wang T; Utama A; Raharjo SB; Yuniadi Y; Tai SS
    BMC Med Genet; 2011 Jun; 12():80. PubMed ID: 21639946
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel CYP2C9 and VKORC1 gene variants associated with warfarin dosage variability in the South African black population.
    Mitchell C; Gregersen N; Krause A
    Pharmacogenomics; 2011 Jul; 12(7):953-63. PubMed ID: 21635147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement.
    Cen HJ; Zeng WT; Leng XY; Huang M; Chen X; Li JL; Huang ZY; Bi HC; Wang XD; He YL; He F; Zhou RN; Zheng QS; Zhao LZ
    Br J Clin Pharmacol; 2010 Aug; 70(2):234-40. PubMed ID: 20653676
    [TBL] [Abstract][Full Text] [Related]  

  • 26. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
    Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
    Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacogenetic impact of VKORC1 and CYP2C9 allelic variants on warfarin dose requirements in a hispanic population isolate.
    Palacio L; Falla D; Tobon I; Mejia F; Lewis JE; Martinez AF; Arcos-Burgos M; Camargo M
    Clin Appl Thromb Hemost; 2010 Feb; 16(1):83-90. PubMed ID: 19567378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Warfarin sensitivity genotyping: a review of the literature and summary of patient experience.
    Moyer TP; O'Kane DJ; Baudhuin LM; Wiley CL; Fortini A; Fisher PK; Dupras DM; Chaudhry R; Thapa P; Zinsmeister AR; Heit JA
    Mayo Clin Proc; 2009 Dec; 84(12):1079-94. PubMed ID: 19955245
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implications of Polymorphisms in the BCKDK and GATA-4 Gene Regions on Stable Warfarin Dose in African Americans.
    Bargal SA; Kight JN; Augusto de Oliveira F; Shahin MH; Langaee T; Gong Y; Hamadeh IS; Cooper-DeHoff RM; Cavallari LH
    Clin Transl Sci; 2021 Mar; 14(2):492-496. PubMed ID: 33278335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population.
    Veenstra DL; You JH; Rieder MJ; Farin FM; Wilkerson HW; Blough DK; Cheng G; Rettie AE
    Pharmacogenet Genomics; 2005 Oct; 15(10):687-91. PubMed ID: 16141794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population.
    Özer M; Demirci Y; Hizel C; Sarikaya S; Karalti İ; Kaspar Ç; Alpan S; Genç E
    Basic Clin Pharmacol Toxicol; 2013 Mar; 112(3):209-14. PubMed ID: 23061746
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.
    Ozer N; Cam N; Tangurek B; Ozer S; Uyarel H; Oz D; Guney MR; Ciloglu F
    Heart Vessels; 2010 Mar; 25(2):155-62. PubMed ID: 20339978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans.
    Takahashi H; Wilkinson GR; Nutescu EA; Morita T; Ritchie MD; Scordo MG; Pengo V; Barban M; Padrini R; Ieiri I; Otsubo K; Kashima T; Kimura S; Kijima S; Echizen H
    Pharmacogenet Genomics; 2006 Feb; 16(2):101-10. PubMed ID: 16424822
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans.
    Kimmel SE; Christie J; Kealey C; Chen Z; Price M; Thorn CF; Brensinger CM; Newcomb CW; Whitehead AS
    Pharmacogenomics J; 2008 Feb; 8(1):53-60. PubMed ID: 17325732
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups.
    Scott SA; Khasawneh R; Peter I; Kornreich R; Desnick RJ
    Pharmacogenomics; 2010 Jun; 11(6):781-91. PubMed ID: 20504253
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Validation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithms.
    Langley MR; Booker JK; Evans JP; McLeod HL; Weck KE
    J Mol Diagn; 2009 May; 11(3):216-25. PubMed ID: 19324988
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes.
    Nowak-Göttl U; Dietrich K; Schaffranek D; Eldin NS; Yasui Y; Geisen C; Mitchell LG
    Blood; 2010 Dec; 116(26):6101-5. PubMed ID: 20833980
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation.
    Wei M; Ye F; Xie D; Zhu Y; Zhu J; Tao Y; Yu F
    Thromb Haemost; 2012 Jun; 107(6):1083-91. PubMed ID: 22534826
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The future of warfarin pharmacogenetics in under-represented minority groups.
    Cavallari LH; Perera MA
    Future Cardiol; 2012 Jul; 8(4):563-76. PubMed ID: 22871196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.
    Sconce EA; Khan TI; Wynne HA; Avery P; Monkhouse L; King BP; Wood P; Kesteven P; Daly AK; Kamali F
    Blood; 2005 Oct; 106(7):2329-33. PubMed ID: 15947090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.